在威尔逊病中用于精确准的合铜的d-penicillamine-loaded MIL-100(Fe)
Wei Fang1,2, Qian Wang1, Houyuan Yang1
1School of Pharmacy, Anhui University of Chinese Medicine Hefei Anhui 230012 China shuchenglin@ahtcm.edu.cn.
RSC advances
|January 22, 2026
概括
这项研究开发了一种用于威尔逊病的新型纳米平台 (MIL-100(Fe) -DPA),有效合过量的铜. 针对性药物输送系统显示了改善肝功能和减少威尔逊病治疗中毒性的承诺.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 威尔逊病 (WD) 是一种影响铜代谢的遗传疾病,导致严重的肝脏和大脑损伤.
- 目前用于WD的化疗法面临着有效性和全身毒性方面的挑战.
- 对于威尔逊病,迫切需要先进的治疗策略.
研究的目的:
- 开发一种新的ROS响应纳米平台,用于针对性地输送d-penicillamine (DPA).
- 评估MIL-100(Fe) -DPA纳米复合物的有效性和安全性,用于威尔逊病治疗.
- 研究这个纳米平台在减少肝脏铜积累和相关的肝损伤方面的潜力.
主要方法:
- 通过将DPA封装在MIL-100(Fe) 孔隙框架中来制造MIL-100(Fe) -DPA.
- 纳米复合材料的结构稳定性,尺寸,血液相容性和药物负载的表征.
- 在铜过载条件下对向药物释放的ROS反应的评估.
- 用动物模型进行体内研究,以评估对肝脏铜水平,肝酶 (ALT,AST) 和肝脏组织损伤的治疗作用.
主要成果:
- 这种MIL-100(Fe) -DPA纳米复合材料表现出稳定的结构,均的尺寸,良好的血液兼容性和高药物负载.
- 该平台展示了ROS响应的药物释放,增强了铜化疗效.
- 在体内研究显示,与免费的DPA相比,肝铜显著减少,肝酶水平改善,肝脏结构恢复.
- 通过纳米平台观察到系统毒性降低.
结论:
- MIL-100(Fe) -DPA是一种有前途的ROS响应纳米平台,用于威尔逊病的精确铜化疗法.
- 这种纳米平台为WD治疗提供了增强的治疗效率和降低系统毒性.
- 这项研究为管理威尔逊病和相关肝脏疾病提供了一种新有效的策略.
更多相关视频
11:04Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides
Published on: September 7, 2019
06:52Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders
Published on: April 28, 2023
相关概念视频
Extraction: Advanced Methods
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
